EPS growth is an important number as it indicates the future prospects of Aldeyra Therapeutics. The EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but the year over year change has been -62.50%. Growth in EPS is an important measure of administration performance because it shows how much money Aldeyra Therapeutics is making for it’s investors or shareholders.
Aldeyra Therapeutics is in the biotechnology industry and healthcare sector. The company CEO is Todd C. Brady. Aldeyra Therapeutics Inc is biotechnology company focused on the development of products for inflammation, inborn errors of metabolism, and other diseases, related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes.
Previous Intraday Performance:
The ALDX shares had a previous change of 2.75% which opened at 8.66 and closed at 8.97. It moved to an intraday high of 9.00 and a low of 8.65.
PR Newswire: Aldeyra Therapeutics to Participate at Citi’s 2018 Global Healthcare Conference
Historical Performance:
Over the last five trading days, ALDX shares returned -1.97% and in the past 30 trading days it returned -24.75%. Over three months, it changed 18.81%. In one year it has changed 30.95% and within that year its 52-week high was 16.70 and its 52-week low was 6.20. ALDX stock is 44.68% above its 52 Week Low.
Our calculations result in a 200 day moving average of 8.68 and a 50 day moving average of 10.98. Right now, ALDX stock is trading 3.31% above its 200 day moving average and may be a good opportunity to buy.
PR Newswire: Aldeyra Therapeutics to Participate at Citi’s 2018 Global Healthcare Conference
Liquidity:
The company has a market cap of $235.4m with 26.2m shares outstanding and a float of 25.8m shares. Trading volume was 97,700 shares and has experienced an average volume of 201,821 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Aldeyra Therapeutics was -1.4 which ended on 31st of December 2017. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.47.
Below was the last reported quarterly earnings per share:
09-30-2018: -0.52
06-30-2018: -0.46
03-31-2018: -0.43
12-31-2017: -0.37
Indicators Also to Watch:
Based on the latest filings, there is 2.00% of insider ownership and 71.80% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.
I calculated the beta to be 0.84
SeekingAlpha: Apellis Pharma down 17% on hiccup in late-stage study of APL-2
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -94.54%, return on assets is -81.55% and price-to-book is 8.23.
Company Score Card:
Results are out of six:
3 : Growth Expectations Result
4 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result
Related Tags: Aldeyra Therapeutics, ALDX, Biotechnology, Healthcare
